Literature DB >> 16949684

Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions.

Alejo Chorny1, Elena Gonzalez-Rey, Niveves Varela, Gema Robledo, Mario Delgado.   

Abstract

The vasoactive intestinal peptide (VIP) is a neuropeptide belonging to the secretin/glucagon family of peptides, which exerts a wide spectrum of immunological functions controlling the homeostasis of immune system through different receptors expressed in various immunocompetent cells. In the last decade, VIP has emerged as a potent anti-inflammatory factor, which exerts its function by regulating the production of both anti- and pro-inflammatory mediators. In this sense, VIP has been proposed as a promising candidate, alternative to other existing treatments, for treating acute and chronic inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis and Crohn's disease. The present work reviews the involvement of the specific receptors and or different transduction pathways and transcription factors in the anti-inflammatory action of VIP, and their implication on its therapeutic effect on inflammatory/autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16949684     DOI: 10.1016/j.regpep.2006.04.021

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  18 in total

1.  Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Linda D Hazlett
Journal:  J Immunol       Date:  2012-06-01       Impact factor: 5.422

2.  Administration of a vasoactive intestinal peptide antagonist enhances the autologous anti-leukemia T cell response in murine models of acute leukemia.

Authors:  Christopher T Petersen; Jian-Ming Li; Edmund K Waller
Journal:  Oncoimmunology       Date:  2017-03-16       Impact factor: 8.110

Review 3.  Anti-inflammatory neuropeptides: a new class of endogenous immunoregulatory agents.

Authors:  Mario Delgado; Doina Ganea
Journal:  Brain Behav Immun       Date:  2008-06-14       Impact factor: 7.217

4.  Vasoactive intestinal peptide promotes gut barrier function against severe acute pancreatitis.

Authors:  Lu Zhongkai; Ye Jianxin; Chen Weichang
Journal:  Mol Biol Rep       Date:  2011-07-03       Impact factor: 2.316

5.  Protected graft copolymer excipient leads to a higher acute maximum tolerated dose and extends residence time of vasoactive intestinal Peptide significantly better than sterically stabilized micelles.

Authors:  Sandra Reichstetter; Gerardo M Castillo; Israel Rubinstein; Akiko Nishimoto-Ashfield; Manshun Lai; Cynthia C Jones; Aryamitra A Banerjee; Aryamitra Banjeree; Alex Lyubimov; Duane C Bloedow; Alexei Bogdanov; Elijah M Bolotin
Journal:  Pharm Res       Date:  2012-12-07       Impact factor: 4.200

6.  Combined administration of secretin and oxytocin inhibits chronic colitis and associated activation of forebrain neurons.

Authors:  Martha G Welch; Muhammad Anwar; Christine Y Chang; Kara J Gross; David A Ruggiero; Hadassah Tamir; Michael D Gershon
Journal:  Neurogastroenterol Motil       Date:  2010-03-04       Impact factor: 3.598

7.  Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice.

Authors:  Simon Studeny; Bopaiah P Cheppudira; Susan Meyers; Elena M Balestreire; Gerard Apodaca; Lori A Birder; Karen M Braas; James A Waschek; Victor May; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-06-17       Impact factor: 3.444

8.  Expression of phosphorylated cAMP response element binding protein (p-CREB) in bladder afferent pathways in VIP-/- mice with cyclophosphamide (CYP)-induced cystitis.

Authors:  Dorthe G Jensen; Simon Studeny; Victor May; James Waschek; Margaret A Vizzard
Journal:  J Mol Neurosci       Date:  2008-02-26       Impact factor: 3.444

9.  Levels of dipeptidyl peptidase IV/CD26 substrates neuropeptide Y and vasoactive intestinal peptide in rheumatoid arthritis patients.

Authors:  Suncica Buljevic; Dijana Detel; Lara Baticic Pucar; Radovan Mihelic; Tomislav Madarevic; Branko Sestan; Jadranka Varljen
Journal:  Rheumatol Int       Date:  2013-07-18       Impact factor: 2.631

10.  Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.

Authors:  Jian-Ming Li; Christopher T Petersen; Jing-Xia Li; Reema Panjwani; Daniel J Chandra; Cynthia R Giver; Bruce R Blazar; Edmund K Waller
Journal:  Cancer Res       Date:  2016-09-26       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.